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Letter to the Editor
Is it Time to Test Metformin in Breast Cancer
Prevention Trials? a Reply to the Authors
To the Editor: We read with great interest the article
by Cazzaniga et al. (1) on the potential use of the in-
sulin sensitizing agent metformin for therapeutic and
chemopreventive purposes in breast cancer. We found
that the safety profile of metformin was inadequately
elicited and poorly supported by the cited references.
This was particularly striking with regard to lactic ac-
idosis, defined by the authors as “the only potential
adverse event in metformin therapy.” The authors fur-
ther refer to this condition in terms of a rare event,
which primarily occurs in patients with renal and he-
patic disorders. The reported evidence was not exhaus-
tive and the only cited reference was taken from an
article published in 1996 (2). Given the current use
of metformin in several common pathologic conditions
associated with insulin resistance (e.g., type 2 diabetes
and polycystic ovary syndrome) as well as the great
potential of this drug in breast cancer therapy and
prevention, the relation between metformin use and
lactic acidosis in both diabetic and non diabetic pa-
tients is in urgent need of clarification particularly in
light of much more recent and comprehensive scientific
evidence.
The Cochrane Collaboration has conducted a system-
atic review evaluating the risk of fatal and nonfatal ac-
idosis attributed to metformin use compared with
placebo and other agents in type 2 diabetes patients.
Salpenter et al. (3) pooled data for a total of 59,321 pa-
tient-years of metformin use and 51,627 patient-years in
the nonmetformin group. They found no evidence of
the association between metformin use and risk of lactic
acidosis.
In nondiabetic patients, lactic acidosis occurs in associ-
ation with pathologic conditions leading to tissue hypox-
ia, such as infections, heart failure, liver failure, and renal
failure. In these cases, mortality is predicted by the sever-
ity of the underlying hypoxia and does not correlate with
metformin accumulation (4, 5).
In conclusion, when referring to the association be-
tween this drug use and lactic acidosis in an evaluation
of the timeliness of testing metformin in breast cancer pre-
vention trials, the following message should be clearly
conveyed: although circumstantial evidence has linked
metformin treatment with lactic acidosis, no causal rela-
tionship has been shown thus far, either in patients with
type 2 diabetes or in nondiabetic patients. Conversely, this
drug has been proven to reduce cardiovascular mortality
in type 2 diabetes patients and, when considered in a pre-
clinical setting, to possess anticarcinogenic properties on
breast, colon, and prostate (1).
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